Prospects for a globally effective HIV-1 vaccine

Vaccine

Volumn 33, Issue , 2015, Pages D4-D12

  Excler, Jean Louis ^a,b   Robb, Merlin L ^a,b   Kim, Jerome H ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

Clinical trial; Correlates; Efficacy; HIV 1; Licensure; Public health; Vaccine

Indexed keywords

ANTIGEN; BLOCKING ANTIBODY; EPITOPE; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; MIFAMURTIDE; MONOCLONAL ANTIBODY; NEF PROTEIN; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; POL PROTEIN; REV PROTEIN; RV 144 VACCINE; SUBUNIT VACCINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

AFRICA; ANTIBODY RESPONSE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL LINEAGE; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; HUMORAL IMMUNITY; IMMUNIZATION; INDEL MUTATION; INFECTION RISK; LYMPHOCYTE PROLIFERATION; MEN WHO HAVE SEX WITH MEN; MUCOSAL IMMUNITY; MUTATION RATE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTECTION; REVIEW; RISK REDUCTION; SOMATIC MUTATION; THAILAND; VACCINATION; VIRUS INHIBITION; VIRUS MUTATION; ANIMAL; ANIMAL MODEL; BLOOD; DISEASE MODEL; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MALE; PRIMATE; TRANSMISSION; VIROLOGY;

AFRICA, SOUTHERN; AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MODELS, ANIMAL; PRIMATES; THAILAND;

EID: 84951566775     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.059     Document Type: Review

References (154)

1. Nitayaphan S., Ngauy V., O'Connell R., Excler J.L. HIV epidemic in Asia: optimizing and expanding vaccine development. Expert Rev Vaccines 2012, 11:805-819.
2. UNAIDS The Gap report 2014, Geneva, Switzerland.
3. McCoy S.I., Kangwende R.A., Padian N.S. Behavior change interventions to prevent HIV infection among women living in low and middle income countries: a systematic review. AIDS Behav 2010, 14:469-482.
4. Dutta A., Wirtz A.L., Baral S., Beyrer C., Cleghorn F.R. Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries. Curr Opin HIV AIDS 2012, 7:362-368.
5. Wamai R.G., Morris B.J., Bailis S.A., Sokal D., Klausner J.D., Appleton R., et al. Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa. J Int AIDS Soc 2011, 14:49.
6. Chi B.H., Adler M.R., Bolu O., Mbori-Ngacha D., Ekouevi D.K., Gieselman A., et al. Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President's Emergency Plan for AIDS Relief. J Acquir Immune Defic Syndr 2012, 60(Suppl. 3):S78-S87.
7. Kim S.C., Becker S., Dieffenbach C., Hanewall B.S., Hankins C., Lo Y.R., et al. Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc 2010, 13:24.
8. Grant R.M., Lama J.R., Anderson P.L., McMahan V., Liu A.Y., Vargas L., et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010, 363:2587-2599.
9. Choopanya K., Martin M., Suntharasamai P., Sangkum U., Mock P.A., Leethochawalit M., et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013, 381:2083-2090.
10. Mastro T.D., Sista N., Abdool-Karim Q. ARV-based HIV prevention for women - where we are in 2014. J Int AIDS Soc 2014, 17:19154.
11. Cohen M.S., Holmes C., Padian N., Wolf M., Hirnschall G., Lo Y.R., et al. HIV treatment as prevention: how scientific discovery occurred and translated rapidly into policy for the global response. Health Aff (Millwood) 2012, 31:1439-1449.
12. Krakower D., Mayer K.H. Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications. Curr HIV/AIDS Rep 2011, 8:241-248.
13. Abdool Karim Q., Abdool Karim S.S., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174.
14. Grant R.M., Anderson P.L., McMahan V., Liu A., Amico K.R., Mehrotra M., et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014, 14:820-829.
15. Van Damme L., Corneli A., Ahmed K., Agot K., Lombaard J., Kapiga S., et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012, 367:411-422.
16. Fauci A.S., Marston H.D. Ending AIDS - is an HIV vaccine necessary?. N Engl J Med 2014, 370:495-498.
17. Beyrer C., Abdool Karim Q. The changing epidemiology of HIV in 2013. Curr Opin HIV AIDS 2013, 8:306-310.
18. Beyrer C., Baral S.D., van Griensven F., Goodreau S.M., Chariyalertsak S., Wirtz A.L., et al. Global epidemiology of HIV infection in men who have sex with men. Lancet 2012, 380:367-377.
19. Baral S.D., Poteat T., Stromdahl S., Wirtz A.L., Guadamuz T.E., Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis 2013, 13:214-222.
20. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011, 25:679-689.
21. Hemelaar J. Implications of HIV diversity for the HIV-1 pandemic. J Infect 2013, 66:391-400.
22. Excler J.L., Robb M.L., Kim J.H. HIV-1 vaccines: challenges and new perspectives. Hum Vaccines Immunother 2014, 10:1734-1746.
23. Excler J.L., Tomaras G.D., Russell N.D. Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS 2013, 8:421-431.
24. Walker B.D., Ahmed R., Plotkin S. Moving ahead an HIV vaccine: use both arms to beat HIV. Nat Med 2011, 17:1194-1195.
25. O'Connell R.J., Excler J.L. HIV vaccine efficacy and immune correlates of risk. Curr HIV Res 2013, 11:450-463.
26. Barouch D.H., Liu J., Li H., Maxfield L.F., Abbink P., Lynch D.M., et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482:89-93.
27. Barouch D.H., Stephenson K.E., Borducchi E.N., Smith K., Stanley K., McNally A.G., et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 2013, 155:531-539.
28. Roederer M., Keele B.F., Schmidt S.D., Mason R.D., Welles H.C., Fischer W., et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 2014, 505:502-508.
29. Zolla-Pazner S. A critical question for HIV vaccine development: which antibodies to induce?. Science 2014, 345:167-168.
30. Mascola J.R. HIV/AIDS: allied responses. Nature 2007, 449:29-30.
31. Su B., Moog C. Which antibody functions are important for an HIV vaccine?. Front Immunol 2014, 5:289.
32. Excler J.L., Ake J., Robb M.L., Kim J.H., Plotkin S.A. Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines. Clin Vaccine Immunol 2014, 21:1023-1036.
33. Sarzotti-Kelsoe M., Bailer R.T., Turk E., Lin C.L., Bilska M., Greene K.M., et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods 2014, 409:131-146.
34. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671.
35. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191:654-665.
36. Gilbert P.B., Peterson M.L., Follmann D., Hudgens M.G., Francis D.P., Gurwith M., et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005, 191:666-677.
37. Gilbert P.B., Ackers M.L., Berman P.W., Francis D.P., Popovic V., Hu D.J., et al. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 2005, 192:974-983.
38. Kim J.H., Excler J.L., Michael N.L. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med 2015, 66:423-437.
39. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
40. Gilbert P.B., Berger J.O., Stablein D., Becker S., Essex M., Hammer S.M., et al. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 2011, 203:969-975.
41. Robb M.L., Rerks-Ngarm S., Nitayaphan S., Pitisuttithum P., Kaewkungwal J., Kunasol P., et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012, 12:531-537.
42. Forthal D.N., Gilbert P.B., Landucci G., Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007, 178:6596-6603.
43. Cicala C., Martinelli E., McNally J.P., Goode D.J., Gopaul R., Hiatt J., et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A 2009, 106:20877-20882.
44. Arthos J., Cicala C., Martinelli E., Macleod K., Van Ryk D., Wei D., et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008, 9:301-309.
45. Karnasuta C., Paris R.M., Cox J.H., Nitayaphan S., Pitisuttithum P., Thongcharoen P., et al. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005, 23:2522-2529.
46. Bonsignori M., Pollara J., Moody M.A., Alpert M.D., Chen X., Hwang K.K., et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012, 86:11521-11532.
47. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.
48. Zolla-Pazner S., deCamp A.C., Cardozo T., Karasavvas N., Gottardo R., Williams C., et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLOS ONE 2013, 8:e53629.
49. Karasavvas N., Billings E., Rao M., Williams C., Zolla-Pazner S., Bailer R.T., et al. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 2012, 28:1444-1457.
50. Zolla-Pazner S., Decamp A., Gilbert P.B., Williams C., Yates N.L., Williams W.T., et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLOS ONE 2014, 9:e87572.
51. Rolland M., Edlefsen P.T., Gottardo R., Montefiori D.C., Zolla-Pazner S., Moody A., et al. Genetic and immunological evidence for a role of Env-V3 antibodies in the RV144 trial. Abstract P03.73 LB, AIDS Vaccine 2013 2013.
52. Gottardo R., Bailer R.T., Korber B.T., Gnanakaran S., Phillips J., Shen X., et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLOS ONE 2013, 8:e75665.
53. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
54. Gray G.E., Allen M., Moodie Z., Churchyard G., Bekker L.G., Nchabeleng M., et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011, 11:507-515.
55. Hammer S.M., Sobieszczyk M.E., Janes H., Karuna S.T., Mulligan M.J., Grove D., et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013, 369:2083-2092.
56. Rolland M., Edlefsen P.T., Larsen B.B., Tovanabutra S., Sanders-Buell E., Hertz T., et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012, 490:417-420.
57. Liao H.X., Bonsignori M., Alam S.M., McLellan J.S., Tomaras G.D., Moody M.A., et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013, 38:176-186.
58. Liu P., Yates N.L., Shen X., Bonsignori M., Moody M.A., Liao H.X., et al. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol 2013, 87:7828-7836.
59. Yates N.L., Liao H.X., Fong Y., Decamp A., Vandergrift N.A., Williams W.T., et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 2014, 6:228ra39.
60. Chung A.W., Ghebremichael M., Robinson H., Brown E., Choi I., Lane S., et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med 2014, 6(228):ra38.
61. O'Connell R.J., Kim J.H., Excler J.L. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development. Expert Rev Vaccines 2014, 1-12.
62. Plotkin S.A., Gilbert P.B. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012, 54:1615-1617.
63. Karasavvas N., Karnasuta C., Ngauy V., Vasan S., Tricharavoj R., de Souza M.S., et al. Investigation of antibody responses induced in RV305 a late boost vaccination of HIV-1 uninfected volunteers that participated in RV144, a Thai trial. P03.68LB, AIDS Vaccine 2013 2013.
64. Akapirat S., Karnasuta C., Madnote S., Savadsuk H., Puangkaew J., Rittiroongrad S., et al. HIV-specific antibody in rectal secretions following late boosts in RV144 participants (RV305). OA11.05, HIV R4P 2014.
65. ® B/E in RV144 vaccinees. OA12.06 LB, HIV R4P 2014.
66. Mastelic B., Garcon N., Del Giudice G., Golding H., Gruber M., Neels P., et al. Predictive markers of safety and immunogenicity of adjuvanted vaccines. Biologicals 2013, 41:458-468.
67. O'Hagan D.T., Ott G.S., De Gregorio E., Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 2012, 30:4341-4348.
68. Leroux-Roels I., Koutsoukos M., Clement F., Steyaert S., Janssens M., Bourguignon P., et al. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three adjuvant systems. Vaccine 2010, 28:7016-7024.
69. Garcon N., Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011, 10:471-486.
70. Vaccari M., Gordon S.N., Fourati S., Schifanella L., Cameron M., Keele B.F., et al. Adjuvant dependent mucosal V2 responses and RAS activation in vaccine induced protection from SIVmac251 acquisition. OA25.01. HIV R4P 2014.
71. McElrath M.J. Selection of potent immunological adjuvants for vaccine construction. Semin Cancer Biol 1995, 6:375-385.
72. Rao M., Onkar S., Peachman K., Padilla-Sanchez V., Yamini G., Jobe O., et al. Potent V2-specific antibodies induced in humans using liposome-encapsulated HIV-1 gp120 recognize a well-exposed V2 epitope on envelope trimer. Abstract 2049. Keystone, HIV Vaccines: Adaptive Immunity and Beyond 2014.
73. Moon J.J., Suh H., Bershteyn A., Stephan M.T., Liu H., Huang B., et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 2011, 10:243-251.
74. Zhao L., Seth A., Wibowo N., Zhao C.X., Mitter N., Yu C., et al. Nanoparticle vaccines. Vaccine 2014, 32:327-337.
75. Nutt S.L., Tarlinton D.M. Germinal center B and follicular helper T cells: siblings, cousins or just good friends?. Nat Immunol 2011, 12:472-477.
76. Moore J.P., Cao Y., Leu J., Qin L., Korber B., Ho D.D. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996, 70:427-444.
77. Mascola J.R., Louder M.K., Surman S.R., Vancott T.C., Yu X.F., Bradac J., et al. Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses 1996, 12:1319-1328.
78. Mascola J.R., Louwagie J., McCutchan F.E., Fischer C.L., Hegerich P.A., Wagner K.F., et al. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis 1994, 169:48-54.
79. Nyambi P.N., Nkengasong J., Lewi P., Andries K., Janssens W., Fransen K., et al. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol 1996, 70:6235-6243.
80. Weber J., Fenyo E.M., Beddows S., Kaleebu P., Bjorndal A. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. J Virol 1996, 70:7827-7832.
81. Hraber P., Korber B.T., Lapedes A.S., Bailer R.T., Seaman M.S., Gao H., et al. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. J Virol 2014, 88:12623-12643.
82. Koff W.C. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Vaccine 2012, 30:4310-4315.
83. Mascola J.R., Haynes B.F. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 2013, 254:225-244.
84. Tomaras G.D., Haynes B.F. Lessons from babies: inducing HIV-1 broadly neutralizing antibodies. Nat Med 2014, 20:583-585.
85. Goo L., Chohan V., Nduati R., Overbaugh J. Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat Med 2014, 20:655-658.
86. Simek M.D., Rida W., Priddy F.H., Pung P., Carrow E., Laufer D.S., et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009, 83:7337-7348.
87. Stamatatos L., Morris L., Burton D.R., Mascola J.R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat Med 2009, 15:866-870.
88. Moore P.L., Crooks E.T., Porter L., Zhu P., Cayanan C.S., Grise H., et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006, 80:2515-2528.
89. Nabel G.J. Designing tomorrow's vaccines. N Engl J Med 2013, 368:551-560.
90. Hessell A.J., Rakasz E.G., Tehrani D.M., Huber M., Weisgrau K.L., Landucci G., et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010, 84:1302-1313.
91. Burton D.R., Hessell A.J., Keele B.F., Klasse P.J., Ketas T.A., Moldt B., et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 2011, 108:11181-11186.
92. Pegu A., Yang Z.Y., Boyington J.C., Wu L., Ko S.Y., Schmidt S.D., et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med 2014, 6:243ra88.
93. Rudicell R.S., Kwon Y.D., Ko S.Y., Pegu A., Louder M.K., Georgiev I.S., et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol 2014, 88:12669-12682.
94. Moldt B., Rakasz E.G., Schultz N., Chan-Hui P.Y., Swiderek K., Weisgrau K.L., et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A 2012, 109:18921-18925.
95. Kwong P.D. Structure-based stabilization of the prefusion closed HIV-1 env trimer [SY05.03]. HIV R4P 2014.
96. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Oliveira T.Y., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333:1633-1637.
97. Burton D.R., Ahmed R., Barouch D.H., Butera S.T., Crotty S., Godzik A., et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012, 12:396-407.
98. Kwong P.D., Mascola J.R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012, 37:412-425.
99. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.P., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
100. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
101. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
102. Yu L., Guan Y. Immunologic basis for long HCDR3s in broadly neutralizing antibodies against HIV-1. Front Immunol 2014, 5:250.
103. McGuire A.T., Dreyer A.M., Carbonetti S., Lippy A., Glenn J., Scheid J.F., et al. HIV antibodies, antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science 2014, 346:1380-1383.
104. Breden F., Lepik C., Longo N.S., Montero M., Lipsky P.E., Scott J.K. Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLOS ONE 2011, 6:e16857.
105. Scheid J.F., Mouquet H., Feldhahn N., Seaman M.S., Velinzon K., Pietzsch J., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458:636-640.
106. Guenaga J., de Val N., Tran K., Feng Y., Satchwell K., Ward A.B., et al. Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties. PLOS Pathog 2015, 11:e1004570.
107. Pugach P., Ozorowski G., Cupo A., Ringe R., Yasmeen A., de Val N., et al. A native-like SOSIP.664 trimer based on a HIV-1 subtype B env gene. J Virol 2015, 89:3380-3395.
108. West A.P., Scharf L., Scheid J.F., Klein F., Bjorkman P.J., Nussenzweig M.C. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 2014, 156:633-648.
109. McCoy L.E., Weiss R.A. Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med 2013, 210:209-223.
110. Huang X., Jin W., Hu K., Luo S., Du T., Griffin G.E., et al. Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. Virology 2012, 423:97-106.
111. Quinnan G.V., Zhang P., Dong M., Chen H., Feng Y.R., Lewis M., et al. Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins. PLOS ONE 2013, 8:e59803.
112. Kovacs J.M., Nkolola J.P., Peng H., Cheung A., Perry J., Miller C.A., et al. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci U S A 2012, 109:12111-12116.
113. Bricault C.A., Kovacs J.M., Nkolola J.P., Yusim K., Giorgi E.E., Shields J.L., et al. A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component. J Virol 2015, 89:2507-2519.
114. Santra S., Muldoon M., Watson S., Buzby A., Balachandran H., Carlson K.R., et al. Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology 2012, 428:121-127.
115. Bonsignori M., Alam S.M., Liao H.X., Verkoczy L., Tomaras G.D., Haynes B.F., et al. HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol 2012, 20:532-539.
116. Liao H.X., Lynch R., Zhou T., Gao F., Alam S.M., Boyd S.D., et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013, 496:469-476.
117. Doria-Rose N.A., Schramm C.A., Gorman J., Moore P.L., Bhiman J.N., DeKosky B.J., et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014, 509:55-62.
118. Jardine J., Julien J.P., Menis S., Ota T., Kalyuzhniy O., McGuire A., et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013, 340:711-716.
119. Johnson P.R., Schnepp B.C., Zhang J., Connell M.J., Greene S.M., Yuste E., et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009, 15:901-906.
120. Schnepp B.C., Johnson P.R. Adeno-associated virus delivery of broadly neutralizing antibodies. Curr Opin HIV AIDS 2014, 9:250-256.
121. Balazs A.B., Chen J., Hong C.M., Rao D.S., Yang L., Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012, 481:81-84.
122. Balazs A.B., Ouyang Y., Hong C.M., Chen J., Nguyen S.M., Rao D.S., et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 2014, 20:296-300.
123. Tongo M., Burgers W.A. Challenges in the design of a T cell vaccine in the context of HIV-1 diversity. Viruses 2014, 6:3968-3990.
124. McDermott A.B., Koup R.A. CD8(+) T cells in preventing HIV infection and disease. AIDS 2012, 26:1281-1292.
125. McMichael A.J., Haynes B.F. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol 2012, 13:423-427.
126. Korber B.T., Letvin N.L., Haynes B.F. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol 2009, 83:8300-8314.
127. Parks C.L., Picker L.J., King C.R. Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS 2013, 8:402-411.
128. Excler J.L., Parks C.L., Ackland J., Rees H., Gust I.D., Koff W.C. Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference. Biologicals 2010, 38:511-521.
129. Koup R.A., Graham B.S., Douek D.C. The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nat Rev Immunol 2011, 11:65-70.
130. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457:87-91.
131. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 2008, 372:1894-1905.
132. Rolland M., Tovanabutra S., deCamp A.C., Frahm N., Gilbert P.B., Sanders-Buell E., et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011, 17:366-371.
133. Fitzgerald D.W., Janes H., Robertson M., Coombs R., Frank I., Gilbert P., et al. An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the step study). J Infect Dis 2011, 203:765-772.
134. Li F., Finnefrock A.C., Dubey S.A., Korber B.T., Szinger J., Cole S., et al. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLOS ONE 2011, 6:e20479.
135. Reynolds M.R., Weiler A.M., Piaskowski S.M., Piatak M., Robertson H.T., Allison D.B., et al. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine 2012, 30:4465-4475.
136. Qureshi H., Ma Z.M., Huang Y., Hodge G., Thomas M.A., DiPasquale J., et al. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb Step trial of a similar HIV-1 vaccine. J Virol 2012, 86:2239-2250.
137. Letvin N.L., Rao S.S., Montefiori D.C., Seaman M.S., Sun Y., Lim S.Y., et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 2011, 3:81ra36.
138. Bakari M., Aboud S., Nilsson C., Francis J., Buma D., Moshiro C., et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 2011, 29:8417-8428.
139. Ratto-Kim S., Currier J.R., Cox J.H., Excler J.L., Valencia-Micolta A., Thelian D., et al. Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens. PLOS ONE 2012, 7:e45840.
140. Santra S., Liao H.X., Zhang R., Muldoon M., Watson S., Fischer W., et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010, 16:324-328.
141. Barouch D.H., O'Brien K.L., Simmons N.L., King S.L., Abbink P., Maxfield L.F., et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010, 16:319-323.
142. Letourneau S., Im E.J., Mashishi T., Brereton C., Bridgeman A., Yang H., et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLOS ONE 2007, 2:e984.
143. Rolland M., Nickle D.C., Mullins J.I. HIV-1 group M conserved elements vaccine. PLOS Pathog 2007, 3:e157.
144. Liu Y., McNevin J., Rolland M., Zhao H., Deng W., Maenza J., et al. Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses. J Infect Dis 2009, 200:1825-1833.
145. Kulkarni V., Valentin A., Rosati M., Rolland M., Mullins J.I., Pavlakis G.N., et al. HIV-1 conserved elements p24CE DNA vaccine induces humoral immune responses with broad epitope recognition in macaques. PLOS ONE 2014, 9:e111085.
146. Stephenson K.E., SanMiguel A., Simmons N.L., Smith K., Lewis M.G., Szinger J.J., et al. Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys. J Virol 2012, 86:11434-11440.
147. Clutton G., Carpov A., Parks C.L., Dean H.J., Montefiori D.C., Hanke T. Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines. AIDS 2014, 28:2495-2504.
148. Ondondo B., Abdul-Jawad S., Bridgeman A., Hanke T. Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice. Clin Vaccine Immunol 2014, 21:1565-1572.
149. Koopman G., Beenhakker N., Nieuwenhuis I., Doxiadis G., Mooij P., Drijfhout J.W., et al. DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. AIDS 2013, 27:2841-2851.
150. Hayton E.J., Rose A., Ibrahimsa U., Del Sorbo M., Capone S., Crook A., et al. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLOS ONE 2014, 9:e101591.
151. Borthwick N., Ahmed T., Ondondo B., Hayes P., Rose A., Ebrahimsa U., et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 2014, 22:464-475.
152. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
153. Hansen S.G., Piatak M., Ventura A.B., Hughes C.M., Gilbride R.M., Ford J.C., et al. Immune clearance of highly pathogenic SIV infection. Nature 2013, 502:100-104.
154. Barouch D.H., Michael N.L. Accelerating HIV-1 vaccine efficacy trials. Cell 2014, 159:969-972.